Literature DB >> 22846843

Failure rates in the hepatocellular carcinoma surveillance process.

Amit G Singal1, Adam C Yopp, Samir Gupta, Celette Sugg Skinner, Ethan A Halm, Eucharia Okolo, Mahendra Nehra, William M Lee, Jorge A Marrero, Jasmin A Tiro.   

Abstract

Hepatocellular carcinoma (HCC) surveillance is underutilized among patients with cirrhosis. Understanding which steps in the surveillance process are not being conducted is essential for designing effective interventions to improve surveillance rates. The aim of our study was to characterize reasons for failure in the HCC surveillance process among a cohort of cirrhotic patients with HCC. We conducted a retrospective cohort study of cirrhotic patients diagnosed with HCC at a large urban safety-net hospital between 2005 and 2011. Patients were characterized by receipt of HCC surveillance over a two-year period before HCC diagnosis. Among patients without HCC surveillance, we classified reasons for failure into four categories: failure to recognize liver disease, failure to recognize cirrhosis, failure to order surveillance, and failure to complete surveillance despite orders. Univariate and multivariate analyses were conducted to identify predictors of failures. We identified 178 patients with HCC, of whom 20% had undergone surveillance. There were multiple points of failure-20% had unrecognized liver disease, 19% had unrecognized cirrhosis, 38% lacked surveillance orders, and 3% failed to complete surveillance despite orders. Surveillance was more likely among patients seen by hepatologists [OR, 6.11; 95% confidence interval (CI), 2.5-14.8] and less likely in those with alcohol abuse (OR, 0.14; 95% CI, 0.03-0.65). Although a retrospective analysis in a safety-net hospital, our data suggest that only one in five patients received surveillance before HCC diagnosis. There are multiple points of failure in the surveillance process, with the most common being failure to order surveillance in patients with known cirrhosis. Future interventions must target multiple failure points in the surveillance process to be highly effective.

Entities:  

Mesh:

Year:  2012        PMID: 22846843      PMCID: PMC3435471          DOI: 10.1158/1940-6207.CAPR-12-0046

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  15 in total

1.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 2.  Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.

Authors:  Amit G Singal; Adam Yopp; Celette S Skinner; Milton Packer; William M Lee; Jasmin A Tiro
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

3.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

4.  Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma.

Authors:  Amit G Singal; Michael L Volk; Mina O Rakoski; Sherry Fu; Grace L Su; Heather McCurdy; Jorge A Marrero
Journal:  J Clin Gastroenterol       Date:  2011-09       Impact factor: 3.062

Review 5.  Recent advances in the treatment of hepatocellular carcinoma.

Authors:  Amit G Singal; Jorge A Marrero
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

6.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

7.  Implementing shared decision-making in routine practice: barriers and opportunities.

Authors:  Margaret Holmes-Rovner; Diane Valade; Catherine Orlowski; Catherine Draus; Barbara Nabozny-Valerio; Susan Keiser
Journal:  Health Expect       Date:  2000-09       Impact factor: 3.377

8.  Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

Authors:  A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

Review 9.  A framework for improving the quality of cancer care: the case of breast and cervical cancer screening.

Authors:  Jane G Zapka; Stephen H Taplin; Leif I Solberg; M Michele Manos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-01       Impact factor: 4.254

10.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

View more
  74 in total

1.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

2.  Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma.

Authors:  Amit G Singal; Akbar K Waljee; Nishant Patel; Emerson Y Chen; Jasmin A Tiro; Jorge A Marrero; Adam C Yopp
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

3.  Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.

Authors:  Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-31       Impact factor: 11.382

Review 4.  Current issues and future trends in surveillance for hepatocellular carcinoma.

Authors:  Robert S Rahimi; Adam C Yopp; Amit G Singal
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

5.  The efficacy and effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.

Authors:  Amit G Singal
Journal:  Hepat Oncol       Date:  2015-04-10

6.  Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study.

Authors:  Ju Dong Yang; Hager Ahmed Mohammed; William S Harmsen; Felicity Enders; Gregory J Gores; Lewis R Roberts
Journal:  J Clin Gastroenterol       Date:  2017-09       Impact factor: 3.062

7.  Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.

Authors:  Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; Jorge A Marrero; Katharine McCallister; Hannah Fullington; Caroline Mejias; Akbar K Waljee; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm
Journal:  Hepatology       Date:  2018-12-14       Impact factor: 17.425

8.  Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

Review 9.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

10.  Earlier presentation and application of curative treatments in hepatocellular carcinoma.

Authors:  Susanna V Ulahannan; Austin G Duffy; Timothy S McNeel; Jonathan K Kish; Lois A Dickie; Osama E Rahma; Katherine A McGlynn; Tim F Greten; Sean F Altekruse
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.